Forecast

There is no analyst data available for this company.

News Go to news feed

RaySearch Laboratories plunges 27% after sales warning

RaySearch Laboratories reported preliminary Q2 figures that fell well short of expectations: net sales declined year-on-year with an organic growth of -8% and operating profit dropped sharply. Management attributed the decline to delayed US deals that have not been cancelled but have not yet been realized. Order intake improved, but investors are pricing in short-term sales uncertainty, sending the stock to a 52-week low. Sentiment is likely to remain muted until the full Q2 report is released unless a timeline is provided for converting the deferred orders. » More on de.investing.com
RaySearch Q1 2026: EPS beats forecast, revenue falls sharply

RaySearch reports Q1 2026 EPS of 1.56 SEK vs. expected 1.46 SEK, while net sales fell to 290 million SEK (−20% y/y), missing forecasts of 317 million SEK. The operating margin remained stable at 23% and the stock rose 1.54% in pre-market trading. The revenue decline was partly attributed to currency effects and lower license revenues; management expects EPS of 0.14–0.21 SEK for the coming quarters and anticipates delayed closings in Q2/Q3. » More on de.investing.com
RaySearch suffers 20% revenue decline in Q1 2026, shares fall sharply

RaySearch reported a 20% revenue decline in Q1 2026 to SEK 290m, missing the SEK 317m forecast. The operating margin remained at 23% (EBIT SEK 68m) despite the revenue drop, while order intake fell 13%. Currency effects and lower license revenues weighed on results, and cash stood at SEK 439m. After the figures, the stock initially fell about 11.1%; management issued EPS forecasts of USD 0.15 for Q2 and USD 0.17 for Q3 2026 and aims to stabilise revenue through higher support income and currency management. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, RaySearch Laboratories B has already paid €0.36 in dividends. The last payout was in May.

Financials

In the last quarter, RaySearch Laboratories B had revenue of €24.57M and net profit of €1.77M

(EUR)	Jun 2026	YoY
Revenue	24.57M	10.19%
Gross profit	16.71M	32.77%
Net profit	1.77M	35.94%
EBITDA	8.27M	153.29%

Fundamentals

Metric	Value
Market capitalization	€574.62M
Number of shares	33.9M
52-week high/low	€24.85 - €13.81
Dividend yield	2.15%
Dividends TTM	€0.36
Beta	0.92
P/E ratio	30.26
PEG ratio	2.94
P/B ratio	8.16
P/S ratio	5.01

Company profile

RaySearch Laboratories AB (publ), ein Medizintechnikunternehmen, entwickelt weltweit Softwarelösungen für die Krebsbehandlung. Es entwickelt und vermarktet RayStation, ein Behandlungsplanungssystem für Behandlungsaktivitäten wie automatisierte Planung, adaptive Therapie, multikriterielle Optimierung, schnelle und genaue Dosisberechnungen, OAR-Dosisreduktion, Robustheit, maschinelles Lernen, VMAT, IMRT, 3D-CRT, virtuelle Simulation, Elektronenstrahltherapie, Tomotherapie, Stereotaktik, Protonentherapie, Kohlenstoffionentherapie und Borneutroneneinfangtherapie. Das Unternehmen entwickelt auch RayPlan, ein Behandlungsplanungssystem zur Unterstützung einer Reihe von Behandlungsplanungsaktivitäten für 3D-CRT, IMRT, VMAT, Tomotherapie und Elektronenstrahltherapie, sowie RayCare, ein Onkologie-Informationssystem zur Unterstützung von Krebsbehandlungsaktivitäten. Darüber hinaus bietet das Unternehmen RayCommand, ein Behandlungssteuerungssystem, das mit verschiedenen Hardwaremodellen kompatibel ist und fortschrittliche Funktionen von Behandlungsgeräten und Softwaresystemen unterstützt, sowie RayIntelligence, ein cloudbasiertes Analysesystem für die Onkologie, das Patientendaten in Erkenntnisse verwandelt. Darüber hinaus bietet das Unternehmen Schulungskurse zu seinen Produkten an. RaySearch Laboratories AB (publ) hat seinen Hauptsitz in Stockholm, Schweden.

Name	RaySearch Laboratories B
CEO	Johan Lof
Headquarters	Stockholm, ab Sweden
Website	raysearchlabs.com
Sector	Health Care
Industry	Health Care Technology
IPO	01/03/2000
Employees	464